Rapid decline of glomerular filtration rate estimated from creatinine (eGFRcrea) is associated with severe clinical endpoints. In contrast to cross-sectionally assessed eGFRcrea, the genetic basis for rapid eGFRcrea decline is largely unknown. To help define this, we meta-analyzed 42 genome-wide association studies from the Chronic Kidney Diseases Genetics Consortium and United Kingdom Biobank to identify genetic loci for rapid eGFRcrea decline. Two definitions of eGFRcrea decline were used: 3 mL/min/1.73m2/year or more (``Rapid3''; encompassing 34,874 cases, 107,090 controls) and eGFRcrea decline 25\% or more and eGFRcrea under 60 mL/min/1.73m2 at follow-up among those with eGFRcrea 60 mL/min/1.73m2 or more at baseline (``CKDi25''; encompassing 19,901 cases, 175,244 controls). Seven independent variants were identified across six loci for Rapid3 and/or CKDi25: consisting of five variants at four loci with genome-wide significance (near UMOD-PDILT (2), PRKAG2, WDR72, OR2S2) and two variants among 265 known eGFRcrea variants (near GATM, LARP4B). All these loci were novel for Rapid3 and/or CKDi25 and our bioinformatic follow-up prioritized variants and genes underneath these loci. The OR2S2 locus is novel for any eGFRcrea trait including interesting candidates. For the five genome-wide significant lead variants, we found supporting effects for annual change in blood urea nitrogen or cystatin-based eGFR, but not for GATM or LARP4B. Individuals at high compared to those at low genetic risk (8-14 vs. 0-5 adverse alleles) had a 1.20-fold increased risk of acute kidney injury (95\% confidence interval 1.08-1.33). Thus, our identified loci for rapid kidney function decline may help prioritize therapeutic targets and identify mechanisms and individuals at risk for sustained deterioration of kidney function.
%0 Journal Article
%1 Gorski2021-xo
%A Gorski, Mathias
%A Jung, Bettina
%A Li, Yong
%A Matias-Garcia, Pamela R
%A Wuttke, Matthias
%A Coassin, Stefan
%A Thio, Chris H L
%A Kleber, Marcus E
%A Winkler, Thomas W
%A Wanner, Veronika
%A Chai, Jin-Fang
%A Chu, Audrey Y
%A Cocca, Massimiliano
%A Feitosa, Mary F
%A Ghasemi, Sahar
%A Hoppmann, Anselm
%A Horn, Katrin
%A Li, Man
%A Nutile, Teresa
%A Scholz, Markus
%A Sieber, Karsten B
%A Teumer, Alexander
%A Tin, Adrienne
%A Wang, Judy
%A Tayo, Bamidele O
%A Ahluwalia, Tarunveer S
%A Almgren, Peter
%A Bakker, Stephan J L
%A Banas, Bernhard
%A Bansal, Nisha
%A Biggs, Mary L
%A Boerwinkle, Eric
%A Bottinger, Erwin P
%A Brenner, Hermann
%A Carroll, Robert J
%A Chalmers, John
%A Chee, Miao-Li
%A Chee, Miao-Ling
%A Cheng, Ching-Yu
%A Coresh, Josef
%A de Borst, Martin H
%A Degenhardt, Frauke
%A Eckardt, Kai-Uwe
%A Endlich, Karlhans
%A Franke, Andre
%A Freitag-Wolf, Sandra
%A Gampawar, Piyush
%A Gansevoort, Ron T
%A Ghanbari, Mohsen
%A Gieger, Christian
%A Hamet, Pavel
%A Ho, Kevin
%A Hofer, Edith
%A Holleczek, Bernd
%A Xian Foo, Valencia Hui
%A Hutri-Kähönen, Nina
%A Hwang, Shih-Jen
%A Ikram, M Arfan
%A Josyula, Navya Shilpa
%A Kähönen, Mika
%A Khor, Chiea-Chuen
%A Koenig, Wolfgang
%A Kramer, Holly
%A Krämer, Bernhard K
%A Kühnel, Brigitte
%A Lange, Leslie A
%A Lehtimäki, Terho
%A Lieb, Wolfgang
%A Lifelines Cohort Study,
%A Regeneron Genetics Center,
%A Loos, Ruth J F
%A Lukas, Mary Ann
%A Lyytikäinen, Leo-Pekka
%A Meisinger, Christa
%A Meitinger, Thomas
%A Melander, Olle
%A Milaneschi, Yuri
%A Mishra, Pashupati P
%A Mononen, Nina
%A Mychaleckyj, Josyf C
%A Nadkarni, Girish N
%A Nauck, Matthias
%A Nikus, Kjell
%A Ning, Boting
%A Nolte, Ilja M
%A O'Donoghue, Michelle L
%A Orho-Melander, Marju
%A Pendergrass, Sarah A
%A Penninx, Brenda W J H
%A Preuss, Michael H
%A Psaty, Bruce M
%A Raffield, Laura M
%A Raitakari, Olli T
%A Rettig, Rainer
%A Rheinberger, Myriam
%A Rice, Kenneth M
%A Rosenkranz, Alexander R
%A Rossing, Peter
%A Rotter, Jerome I
%A Sabanayagam, Charumathi
%A Schmidt, Helena
%A Schmidt, Reinhold
%A Schöttker, Ben
%A Schulz, Christina-Alexandra
%A Sedaghat, Sanaz
%A Shaffer, Christian M
%A Strauch, Konstantin
%A Szymczak, Silke
%A Taylor, Kent D
%A Tremblay, Johanne
%A Chaker, Layal
%A van der Harst, Pim
%A van der Most, Peter J
%A Verweij, Niek
%A Völker, Uwe
%A Waldenberger, Melanie
%A Wallentin, Lars
%A Waterworth, Dawn M
%A White, Harvey D
%A Wilson, James G
%A Wong, Tien-Yin
%A Woodward, Mark
%A Yang, Qiong
%A Yasuda, Masayuki
%A Yerges-Armstrong, Laura M
%A Zhang, Yan
%A Snieder, Harold
%A Wanner, Christoph
%A Böger, Carsten A
%A Köttgen, Anna
%A Kronenberg, Florian
%A Pattaro, Cristian
%A Heid, Iris M
%D 2021
%I Elsevier BV
%J Kidney Int.
%K acute association decline disease; eGFRcrea end-stage genome-wide injury; kidney rapid study;
%N 4
%P 926--939
%T Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline
%V 99
%X Rapid decline of glomerular filtration rate estimated from creatinine (eGFRcrea) is associated with severe clinical endpoints. In contrast to cross-sectionally assessed eGFRcrea, the genetic basis for rapid eGFRcrea decline is largely unknown. To help define this, we meta-analyzed 42 genome-wide association studies from the Chronic Kidney Diseases Genetics Consortium and United Kingdom Biobank to identify genetic loci for rapid eGFRcrea decline. Two definitions of eGFRcrea decline were used: 3 mL/min/1.73m2/year or more (``Rapid3''; encompassing 34,874 cases, 107,090 controls) and eGFRcrea decline 25\% or more and eGFRcrea under 60 mL/min/1.73m2 at follow-up among those with eGFRcrea 60 mL/min/1.73m2 or more at baseline (``CKDi25''; encompassing 19,901 cases, 175,244 controls). Seven independent variants were identified across six loci for Rapid3 and/or CKDi25: consisting of five variants at four loci with genome-wide significance (near UMOD-PDILT (2), PRKAG2, WDR72, OR2S2) and two variants among 265 known eGFRcrea variants (near GATM, LARP4B). All these loci were novel for Rapid3 and/or CKDi25 and our bioinformatic follow-up prioritized variants and genes underneath these loci. The OR2S2 locus is novel for any eGFRcrea trait including interesting candidates. For the five genome-wide significant lead variants, we found supporting effects for annual change in blood urea nitrogen or cystatin-based eGFR, but not for GATM or LARP4B. Individuals at high compared to those at low genetic risk (8-14 vs. 0-5 adverse alleles) had a 1.20-fold increased risk of acute kidney injury (95\% confidence interval 1.08-1.33). Thus, our identified loci for rapid kidney function decline may help prioritize therapeutic targets and identify mechanisms and individuals at risk for sustained deterioration of kidney function.
@article{Gorski2021-xo,
abstract = {Rapid decline of glomerular filtration rate estimated from creatinine (eGFRcrea) is associated with severe clinical endpoints. In contrast to cross-sectionally assessed eGFRcrea, the genetic basis for rapid eGFRcrea decline is largely unknown. To help define this, we meta-analyzed 42 genome-wide association studies from the Chronic Kidney Diseases Genetics Consortium and United Kingdom Biobank to identify genetic loci for rapid eGFRcrea decline. Two definitions of eGFRcrea decline were used: 3 mL/min/1.73m2/year or more (``Rapid3''; encompassing 34,874 cases, 107,090 controls) and eGFRcrea decline 25\% or more and eGFRcrea under 60 mL/min/1.73m2 at follow-up among those with eGFRcrea 60 mL/min/1.73m2 or more at baseline (``CKDi25''; encompassing 19,901 cases, 175,244 controls). Seven independent variants were identified across six loci for Rapid3 and/or CKDi25: consisting of five variants at four loci with genome-wide significance (near UMOD-PDILT (2), PRKAG2, WDR72, OR2S2) and two variants among 265 known eGFRcrea variants (near GATM, LARP4B). All these loci were novel for Rapid3 and/or CKDi25 and our bioinformatic follow-up prioritized variants and genes underneath these loci. The OR2S2 locus is novel for any eGFRcrea trait including interesting candidates. For the five genome-wide significant lead variants, we found supporting effects for annual change in blood urea nitrogen or cystatin-based eGFR, but not for GATM or LARP4B. Individuals at high compared to those at low genetic risk (8-14 vs. 0-5 adverse alleles) had a 1.20-fold increased risk of acute kidney injury (95\% confidence interval 1.08-1.33). Thus, our identified loci for rapid kidney function decline may help prioritize therapeutic targets and identify mechanisms and individuals at risk for sustained deterioration of kidney function.},
added-at = {2024-09-10T11:54:51.000+0200},
author = {Gorski, Mathias and Jung, Bettina and Li, Yong and Matias-Garcia, Pamela R and Wuttke, Matthias and Coassin, Stefan and Thio, Chris H L and Kleber, Marcus E and Winkler, Thomas W and Wanner, Veronika and Chai, Jin-Fang and Chu, Audrey Y and Cocca, Massimiliano and Feitosa, Mary F and Ghasemi, Sahar and Hoppmann, Anselm and Horn, Katrin and Li, Man and Nutile, Teresa and Scholz, Markus and Sieber, Karsten B and Teumer, Alexander and Tin, Adrienne and Wang, Judy and Tayo, Bamidele O and Ahluwalia, Tarunveer S and Almgren, Peter and Bakker, Stephan J L and Banas, Bernhard and Bansal, Nisha and Biggs, Mary L and Boerwinkle, Eric and Bottinger, Erwin P and Brenner, Hermann and Carroll, Robert J and Chalmers, John and Chee, Miao-Li and Chee, Miao-Ling and Cheng, Ching-Yu and Coresh, Josef and de Borst, Martin H and Degenhardt, Frauke and Eckardt, Kai-Uwe and Endlich, Karlhans and Franke, Andre and Freitag-Wolf, Sandra and Gampawar, Piyush and Gansevoort, Ron T and Ghanbari, Mohsen and Gieger, Christian and Hamet, Pavel and Ho, Kevin and Hofer, Edith and Holleczek, Bernd and Xian Foo, Valencia Hui and Hutri-K{\"a}h{\"o}nen, Nina and Hwang, Shih-Jen and Ikram, M Arfan and Josyula, Navya Shilpa and K{\"a}h{\"o}nen, Mika and Khor, Chiea-Chuen and Koenig, Wolfgang and Kramer, Holly and Kr{\"a}mer, Bernhard K and K{\"u}hnel, Brigitte and Lange, Leslie A and Lehtim{\"a}ki, Terho and Lieb, Wolfgang and {Lifelines Cohort Study} and {Regeneron Genetics Center} and Loos, Ruth J F and Lukas, Mary Ann and Lyytik{\"a}inen, Leo-Pekka and Meisinger, Christa and Meitinger, Thomas and Melander, Olle and Milaneschi, Yuri and Mishra, Pashupati P and Mononen, Nina and Mychaleckyj, Josyf C and Nadkarni, Girish N and Nauck, Matthias and Nikus, Kjell and Ning, Boting and Nolte, Ilja M and O'Donoghue, Michelle L and Orho-Melander, Marju and Pendergrass, Sarah A and Penninx, Brenda W J H and Preuss, Michael H and Psaty, Bruce M and Raffield, Laura M and Raitakari, Olli T and Rettig, Rainer and Rheinberger, Myriam and Rice, Kenneth M and Rosenkranz, Alexander R and Rossing, Peter and Rotter, Jerome I and Sabanayagam, Charumathi and Schmidt, Helena and Schmidt, Reinhold and Sch{\"o}ttker, Ben and Schulz, Christina-Alexandra and Sedaghat, Sanaz and Shaffer, Christian M and Strauch, Konstantin and Szymczak, Silke and Taylor, Kent D and Tremblay, Johanne and Chaker, Layal and van der Harst, Pim and van der Most, Peter J and Verweij, Niek and V{\"o}lker, Uwe and Waldenberger, Melanie and Wallentin, Lars and Waterworth, Dawn M and White, Harvey D and Wilson, James G and Wong, Tien-Yin and Woodward, Mark and Yang, Qiong and Yasuda, Masayuki and Yerges-Armstrong, Laura M and Zhang, Yan and Snieder, Harold and Wanner, Christoph and B{\"o}ger, Carsten A and K{\"o}ttgen, Anna and Kronenberg, Florian and Pattaro, Cristian and Heid, Iris M},
biburl = {https://puma.scadsai.uni-leipzig.de/bibtex/2a578bec58e25fcc4df54bbf4ef6a5e92/scadsfct},
copyright = {http://creativecommons.org/licenses/by-nc-nd/4.0/},
interhash = {22a11684cc1abaae8cebc541ee0d34d3},
intrahash = {a578bec58e25fcc4df54bbf4ef6a5e92},
journal = {Kidney Int.},
keywords = {acute association decline disease; eGFRcrea end-stage genome-wide injury; kidney rapid study;},
language = {en},
month = apr,
number = 4,
pages = {926--939},
publisher = {Elsevier BV},
timestamp = {2024-09-10T11:54:51.000+0200},
title = {Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline},
volume = 99,
year = 2021
}